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Abstract
 
Apo E is a key molecule in the lipoprotein metabolism; thus,
genetic manipulation of apo E may prove useful in the
treatment of hypercholesterolemia. To test the feasibility of
this idea, we have generated low density lipoprotein recep-
tor (LDLR) knockout mice that overexpress the rat apo E
 
transgene (
 
ETg
 
1
 
/
 
1
 
:LDLRKO
 
)
 
, and compared their plasma
lipoprotein profiles with those of nonexpressing LDLR
knockout mice 
 
(
 
ETg
 
2
 
/
 
2
 
:LDLRKO
 
)
 
. On a normal chow diet,
the mean plasma cholesterol level of 
 
ETg
 
1
 
/
 
1
 
:LDLRKO
 
 
 
mice
was significantly lower than that of 
 
ETg
 
2
 
/
 
2
 
:LDLRKO
 
 
 
mice
 
(189 versus 240 mg/dl, 
 
P
 
 
 
,
 
 0.01). The LDL fraction was se-
lectively reduced in the 
 
ETg
 
1
 
/
 
1
 
:LDLRKO
 
 mice. Despite the
challenge with an atherogenic diet, cholesterol lowering was
persistently observed and fatty streak lesions in the aortic
sinus were significantly suppressed in the mice overexpress-
ing apo E. These results imply that stimulation of hepatic
production of apo E may be used as a promising adjunctive
therapy for homozygous familial hypercholesterolemia. 
 
(
 
J.
Clin. Invest.
 
 1998. 102:386–394.) Key words: apo E 
 
• 
 
low
density lipoprotein receptor 
 
• 
 
hypercholesterolemia 
 
• 
 
knock-
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• 
 
atherosclerosis
 
Introduction
 
Apo E plays a crucial role in the metabolism of plasma lipo-
proteins (1). Apo E is produced primarily by the liver and dis-
tributed in all classes of lipoproteins. In particular, the plasma
metabolism of triglyceride (TG)
 
1
 
-rich lipoproteins such as chy-
lomicron, VLDL, and intermediate density lipoprotein (IDL)
is profoundly influenced by apo E. Several distinct mecha-
nisms have been proposed to explain the role of apo E in the
metabolism of TG-rich lipoproteins. First, apo E binds to the
low density lipoprotein receptor (LDLR) with a high affinity,
thereby facilitating the LDLR-mediated hepatic lipoprotein
uptake (2, 3). Second, apo E binds to cell surface proteogly-
cans, thereby sequestering the apo E–containing lipoproteins
to the surface of cells such as hepatocytes and vascular endo-
thelial cells in the space of Disse of the liver (4). Third, evi-
dence suggests that other endocytic lipoprotein receptors are
involved in the hepatic uptake of chylomicron remnants (CR),
lipoproteins extremely rich in apo E (5, 6). Herz and his col-
leagues have shown that LDLR-related protein, a multifunc-
tional behemoth receptor belonging to the LDLR gene family,
is responsible for the hepatic uptake of CR in the absence of
the LDLR (7–9).
Therapeutic application of this property of apo E has been
vigorously sought. We and Mahley et al. demonstrated a tran-
sient acute reduction in plasma cholesterol levels by 
 
z 
 
20–40%
after intravenous administration of purified apo E (6–70 mg)
into Watanabe heritable hyperlipidemic rabbits, an animal
lacking normal LDLR (10, 11). Repeated injection of apo E
(10 mg) three times a week, however, did not affect the plasma
cholesterol levels, even though the progression of atheroscle-
rosis was suppressed by 50% (12).
To know whether sustained supply of exogenous apo E has
a cholesterol-lowering effect, we developed a line of transgenic
mice that overexpress rat apo E under control of metallothio-
nein promoter (
 
ETg
 
) (13). The plasma levels of total cholesterol
(TC) and TG were reduced in these mice particularly after
treatment with zinc, which induces the expression of the trans-
gene, even after feeding with a high-fat, high-cholesterol diet.
The cholesterol lowering may result from augmented hepatic
uptake of the lipoproteins, because 
 
125
 
I-labeled VLDL or LDL
were cleared from the plasma faster in these 
 
ETg
 
 mice (14). In
addition, the plasma excursions of retinyl ester, an indicator of
chylomicron and CR, were markedly suppressed in the 
 
ETg
 
mice, after intragastric bolus administration of retinol (14).
Based on these results, we proposed that the overexpressed
apo E enhances the plasma clearance of lipoproteins of both
hepatic and intestinal origin. However, whether or not the
pathway by which this clearance is mediated involves the
LDLR remains unknown.
The present study was undertaken to test the feasibility of
the idea that genetic manipulation of apo E is useful for the
treatment of hypercholesterolemia arising from the LDLR de-
ficiency. We have cross-bred the 
 
ETg
 
 mice to LDLR knockout
(
 
LDLRKO
 
) mice, generated 
 
LDLRKO
 
 mice possessing the
apo E transgene in a heterozygous (
 
ETg
 
1
 
/
 
2
 
:LDLRKO
 
) or ho-
mozygous form (
 
ETg
 
1
 
/
 
1
 
:LDLRKO
 
), and compared their
plasma lipoprotein metabolism and atherosclerosis with those
of nonexpressing 
 
LDLRKO
 
 (
 
ETg
 
2
 
/
 
2
 
:LDLRKO
 
) mice.
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1. 
 
Abbreviations used in this paper:
 
 CR, chylomicron remnants; FCR,
fractional catabolic rate; HPLC, high performance liquid chromatog-
raphy; IDL, intermediate density lipoprotein; LDLR, low density li-
poprotein receptor; SRID, single radial immunodiffusion; TC, total
cholesterol; TG, triglyceride.
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Methods
 
Mice.
 
Generation of 
 
ETg
 
 (13) and 
 
LDLRKO
 
 mice (15) were de-
scribed in the indicated references. PCR was performed to determine
the wild-type and mutated LDLR allele using the following sets of
primers: primer A (5
 
9
 
-GATGCCAGGATGGCAA-3
 
9
 
) and primer B
(5
 
9
 
-CGCAGTGCTCCTCATCTGAC-3
 
9
 
), yielding a 354-bp frag-
ment for the wild-type allele and a 1.7-kb fragment for the dis-
rupted allele; and primer C (5
 
9
 
-GATTGGGAAGACAATAGCAG-
GCATGC-3
 
9
 
) and primer D (5
 
9
 
-GGCAAGATGGCTCAGCAAG-
CAAGCAAAGGC-3
 
9
 
), yielding a 1.49-kb fragment for the dis-
rupted allele. Southern blot analyses for the apo E transgene was
described previously (13). The radioactivities were measured by
BAS2000 (Fuji Film, Tokyo, Japan) to discriminate between the het-
erozygotes and homozygotes. Male 
 
LDLRKO
 
 mice were mated to
female 
 
ETg
 
 mice. The resulting offspring, which were heterozygous
for the apo E transgene and were obligatorily heterozygous for the
disrupted LDLR locus (
 
ETg
 
1
 
/
 
2
 
:LDLR
 
1
 
/
 
2
 
), were further bred to 
 
LDL-
RKO
 
 mice to produce 
 
LDLRKO
 
 mice heterozygous for the apo E
transgene (
 
ETg
 
1
 
/
 
2
 
:LDLR
 
2
 
/
 
2
 
 
 
5
 
 
 
ETg
 
1
 
/
 
2
 
:LDLRKO
 
). Brother–sister
mating of the 
 
ETg
 
1
 
/
 
2
 
:LDLRKO
 
 mice was performed to generate
 
ETg
 
2
 
/
 
2
 
:LDLRKO
 
, 
 
ETg
 
1
 
/
 
2
 
:LDLRKO
 
, and 
 
ETg
 
1
 
/
 
1
 
:LDLRKO
 
 mice
with comparable genetic background: 50% from C57BL/6J, 37.5%
from 129Sv, and 12.5% from DBA/2.
Mice were maintained on a 12-h dark/light cycle and were al-
lowed access to food and water ad libitum. Two diets were used: (
 
a
 
) a
normal chow diet (Lab Diet 5002, PMI Feeds, Inc., St. Louis, MO)
that contained 4.5% animal fat and 0.025% cholesterol, 1.16 mM Zn,
1.36 mM Mn, 0.27 mM Cu, 0.01 mM Fe, and 0.04 mM Cr; (
 
b
 
) a 1.25%
cholesterol/atherogenic diet (three parts of the normal diet mixed
with one part of a cholesterol, cocoa butter, casein, and sodium cho-
late diet [Thomas Hartroft diet; PMI Foods Inc.]). The final diet con-
tained 1.25% cholesterol, 7.5% cocoa butter, 7.5% casein, and 0.5%
sodium cholate (16). For induction of the metallothionein promoter,
water supplemented with 20 mM ZnSO
 
4
 
 was administered for 
 
.
 
 2 wk
(13). Experiments were performed in accordance with institutional
guidelines. Unless otherwise stated, mice aged between 12–16 wk
were used for the experiments.
 
Plasma lipid analysis.
 
Blood was collected from the retroorbital
plexus into a tube containing EDTA after a 12-h fast, and plasma was
separated by centrifugation and mixed with 1/500 vol of a solution
containing 60 mg/ml of benzamidine. TC and TG concentrations were
determined enzymatically using kits (Determiner TC555 and Deter-
miner TG555; Kyowa Medex, Tokyo, Japan). For lipoprotein analy-
ses, the plasma was immediately applied to high performance liquid
chromatography (HPLC) or sequential ultracentrifugation. HPLC
analyses were performed according to a modified method of Hara
and Okazaki (16). 5 
 
m
 
l of plasma was applied to a combined column
system composed of two TSK gel Lipopropacks (TOSOH; Tokyo, Ja-
pan) in tandem, and eluted with the supplied buffer (TSK eluent LP1;
TOSOH) at a rate of 0.5 ml/min. TC concentrations in the effluents
were monitored using a kit (Determiner TC555). Areas under the
elution curves for HDL and non-HDL peaks were determined. These
values and plasma TC levels were used to calculate non–HDL- and
HDL-cholesterol concentrations.
 
Quantitation of apo B.
 
Plasma apo B concentrations were deter-
mined by isopropanol precipitation method as described (17). In
brief, 100 
 
m
 
l of plasma was obtained from an individual mouse and ul-
tracentrifuged at a density of 1.063 g/ml. An aliquot of the top 
 
d
 
 
 
,
 
1.063 g/ml lipoprotein fraction was mixed with an equal volume of
isopropanol in a microfuge tube, incubated at room temperature for
1 h, and centrifuged at 10,000 
 
g
 
 for 15 min. The resulting protein pel-
lets were solubilized in 0.1 N NaOH, and protein concentrations were
determined by a kit (BCA protein assay reagent; Pierce, Rockford,
IL). In parallel, apo B concentrations were determined by a single ra-
dial immunodiffusion (SRID) technique using a kit designed for mea-
surement of human apo B levels (Apo B plate ‘Daiichi’; Daiichi Pure
Chemicals, Tokyo, Japan), according to a manufacturer’s instruction
(18). When the same amounts of LDL apo B were applied to the
plates, mouse LDL apo B produced a 8.7-fold larger precipitation
ring in diameter than human LDL apo B. The results of the isopro-
panol precipitation method were correlated with those of the SRID
method with 
 
r
 
2
 
 
 
.
 
 0.99; 
 
n
 
 
 
5
 
 9.
 
Quantitation of apo E.
 
Immunoblot analyses were performed to
determine plasma apo E levels. 1 
 
m
 
l of plasma was subjected to both
SDS/3–15% PAGE and isoelectric focusing (IEF) (Phenotyping apo
E IEF system; Joko, Tokyo, Japan) (19). After proteins were electro-
phoretically transferred to nitrocellulose filters (Hybond ECL
 
®
 
; Am-
ersham Corp., Arlington Heights, IL) in a buffer containing 20 mM
Tris, 150 mM glycine, 0.02% SDS, and 20% methanol at 200 mA for 6 h,
immunoblotting was performed using a rabbit anti–rat apo E poly-
clonal antibody as the first antibody and 
 
125
 
I-protein A (2,000 cpm/ng,
0.5 
 
m
 
g/ml; Amersham Corp.) as described (13). The radioactive im-
ages of the filters were analyzed by BAS2000. Apo E was purified
from either rat or mouse plasma, as previously described (10), and
used for calibration.
The following four variables were measured: X, relative radioac-
tivity of the sample apo E compared to the standard rat apo E on
SDS-PAGE; Y, proportion of the radioactivities in rat apo E (three
bands together) in all the apo E radioactivities (rat plus mouse) on
IEF; A, radioactivity of the standard rat apo E; and B, the antibody’s
immunoreactivity for rat apo E compared to that for mouse apo E.
Rat and mouse apo E concentrations were calculated from the fol-
lowing formulas: Rat apo E concentration 
 
5
 
 X 
 
3
 
 Y/A; Mouse apo E
concentration 
 
5
 
 B 
 
3
 
 X 
 
3
 
 (1 
 
2
 
 Y)/A.
 
Analyses of plasma lipoprotein and apolipoproteins.
 
Preparative
ultracentrifugation was performed to obtain CM
 
1
 
VLDL (
 
d
 
 
 
,
 
 1.006
g/ml), IDL (
 
d
 
 1.006–1.019 g/ml), LDL (
 
d
 
 1.019–1.063 g/ml) and HDL
(
 
d
 
 1.063–1.21 g/ml) from the pooled plasma as described (20). TC
contents were measured and represented as mg/dl of original plasma.
After dialysis against saline containing 0.2 mM EDTA and 1 mM
PMSF, each lipoprotein fraction was delipidated overnight at 
 
2
 
20
 
8
 
C
with 20 vol of ice-cold ethanol-diethyl ether (3:1, vol/vol), and the
apolipoproteins were pelleted by centrifugation for 20 min at 
 
2
 
10
 
8
 
C,
1,000 
 
g
 
 (21). The pellets were extracted twice with cold anhydrous di-
ethyl ether, and subjected to SDS/3–15% PAGE. Proteins were visu-
alized by staining with Commassie brilliant blue. The intensities of
the bands were determined by densitometric scanning and quanti-
tated by National Institutes of Health Image software (Bethesda, MD).
 
Plasma lipoprotein kinetics.
 
After a 12-h fast, blood was obtained
from 
 
ETg
 
2
 
/
 
2
 
:LDLRKO
 
 or 
 
ETg
 
1
 
/
 
1
 
:LDLRKO
 
 mice (
 
n
 
 
 
5
 
 10) that had
been maintained on water supplemented with zinc and a normal
chow, and pooled for lipoprotein isolation. VLDL (
 
d
 
 
 
,
 
 1.006 g/ml)
and LDL (
 
d
 
 1.019–1.063 g/ml) were isolated by ultracentrifugation
and refloated at the same density to increase the purity. VLDL ob-
tained from 
 
ETg
 
2
 
/
 
2:LDLRKO or ETg1/1:LDLRKO mice are de-
noted as E2VLDL or E1VLDL, respectively. These lipoproteins and
the infranatant d . 1.063 g/ml fraction were dialyzed against saline
containing 1 mM sodium phosphate, pH 7.4, 0.2 mM EDTA, and 1 mM
PMSF. The lipoproteins were labeled with 125I by iodine monochlo-
ride method (22), and dialyzed as described above. After removing
EDTA and PMSF by dialysis against PBS, the labeled lipoproteins
were mixed with the d . 1.063 g/ml fraction, and diluted with PBS
containing 10 mg/ml BSA to 40 mg/ml. 100 ml (equivalent to 4 mg pro-
tein of the lipoprotein) was injected as a bolus into the jugular vein of
mice that had been maintained on water containing zinc for 2 wk, un-
der anesthesia with pentobarbital. Subsequently, blood was collected
from the retroorbital plexus at the indicated times. Apo B–associated
radioactivities were determined by the isopropanol precipitation
method as described (14). The value at 1 min after injection was used
as 100%. Fractional catabolic rate (FCR) and production rate were
calculated according to Matthews (23).
Vitamin A fat tolerance test. After a 4-h fast, 100 ml of Chocola
A® (Eisai Co., Ltd.; Tokyo, Japan) containing 2 mg of retinyl palmi-
tate and 10.6 mg castor oil was administered as a bolus through a gas-
tric cannula to mice that had been maintained on water supple-
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mented with zinc, without anesthesia. Blood was collected from the
retroorbital plexus at the indicated times. Plasma was immediately
separated and stored wrapped in foil at 2208C. After extraction with
hexane from pooled plasma, the lipids were subjected to HPLC for
the measurement of retinyl palmitate and retinol, as previously de-
scribed (14).
Pathology. The hearts and attached aortas were removed, fixed
with saline containing 4% formalin, embedded in 25% gelatin, and
sectioned as described (24). Briefly, 10 mm cross-sections were taken
sequentially, starting just above the aortic valve and moving along the
ascending aorta. Five sections, each separated by 120 mm, were used
to evaluate the lesions. Fatty streak lesions were stained using Oil
Red O. The lesion area of each section was estimated by a digitizing
tablet (NEC PC-8875 personal TABLET).
Statistics. Student’s t test was used to compare the values be-
tween two groups.
Results
Expression of rat apo E. Immunoblot analyses were per-
formed to measure the plasma concentration of apo E (Fig. 1).
Fig. 1 A compares the intensities of bands corresponding to
apo E purified from mice and rats, when the same amounts (75
ng) were loaded to the gels; the antibody had twofold higher
immunoreactivity for rat apo E than for mouse apo E. Fig. 1 B
shows immunoblots of SDS-PAGE (top) and IEF (bottom) for
the plasma apo E of the three types of mice before and after
zinc treatment. SDS-PAGE revealed that plasma apo E levels
were higher in the mice having the rat apo E transgene than
those without it in the following order before zinc treatment:
ETg1/1:LDLRKO . ETg1/2:LDLRKO . ETg2/2:LDLRKO.
After zinc treatment, plasma apo E levels were further in-
creased in the ETg1/2:LDLRKO mice. Upon IEF, mouse apo
E was focused as a single band, and rat apo E was focused as
three bands that were more acidic than mouse apo E. Presum-
ably, the most basic band of rat apo E is nonsialidated apo E
and the second and third bands are with one and two mole-
cules of sialic acid, respectively. Furthermore, the IEF results
confirm that rat apo E was present only in the ETg1/2:LDL-
RKO and ETg1/1:LDLRKO mice, but not in the ETg2/2:
LDLRKO.
Table I summarizes the calculated values for the plasma
levels of rat and mouse apo E. Before zinc treatment, the
ETg1/2:LDLRKO and ETg1/1:LDLRKO mice had rat apo E
in the plasma in amounts comparable to 50% of mouse endog-
enous apo E. The ETg1/1:LDLRKO mice had 40% higher
concentrations of rat apo E than the ETg1/2:LDLRKO mice.
After zinc treatment, the rat apo E levels were increased by
38% in the ETg1/2:LDLRKO mice and by 23% in the ETg1/1:
Figure 1. Immunoblot analyses of plasma apo E in ETg2/2:LDLRKO (2/2), ETg1/2:LDLRKO (1/2), and ETg1/1:LDLRKO mice (1/1) 
maintained on a normal chow. (A) Difference of the immunoreactivity of the antibody. The same amount of rat and mouse apo E (75 ng) was 
subjected to SDS-PAGE. (B) Immunoblots of apo E separated by SDS-PAGE and IEF. Blood was collected from four mice with the indicated 
genotypes after a 12-h fast, before and after treatment with zinc. 1 ml of pooled plasma was subjected to SDS-PAGE and IEF analyses. (C) Im-
munoblots of apo E in VLDL, IDL, LDL, and HDL. Lipoproteins were separated from pooled plasma (n 5 10) after treatment with zinc by se-
quential ultracentrifugation. Each lipoprotein fraction equivalent to 2 ml of original plasma was subjected to SDS-PAGE.
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LDLRKO mice. But the mouse apo E levels were decreased
in the ETg1/1:LDLRKO mice; therefore, the combined apo E
concentrations were not changed.
Fig. 1 C illustrates the combined apo E levels in each lipo-
protein fraction from the three types of mice treated with zinc.
In any lipoprotein classes, the LDLRKO mice with rat apo E
transgene had more apo E than the LDLRKO mice without
the transgene. The apo E contents were highest in LDL frac-
tion irrespective of the presence of the transgene. Mild gene-
dosage effects were seen in VLDL and IDL fraction.
Plasma lipoprotein profiles. To determine whether consti-
tutive expression of the apo E transgene alters plasma lipid
levels, the plasma TC and TG levels were compared between
the three types of mice, before and after zinc treatment (Table
II). Before zinc treatment, neither plasma TC nor TG differed
significantly between these mice. After zinc treatment for 2 wk,
the plasma TC levels decreased by 20% in the ETg1/2:LDL-
RKO and by 25% in the ETg1/1:LDLRKO mice, but not in
the ETg2/2:LDLRKO mice. Such cholesterol lowering was
largely attributable to the reduction in the non–HDL-C as
shown in Fig. 2; the non–HDL-C was reduced by 20% in the
ETg1/2:LDLRKO mice, and by 32% in the ETg1/1:LDLRKO
mice (Table II).
To further determine which lipoprotein fraction was af-
fected by the expression of rat apo E, we measured the TC and
apo B contents in the lipoproteins isolated from the three
types of mice treated with zinc (Table III). The most outstand-
ing changes were observed in the TC and apo B-100 contents
in the LDL fraction. TC contents in the LDL were reduced by
25% in the ETg1/2:LDLRKO mice and by 39% in the ETg1/1:
LDLRKO mice; apo B-100 contents in the LDL were reduced
by 23% in the ETg1/2:LDLRKO mice, and by 43% in the
ETg1/1:LDLRKO mice. Thus, the changes in the LDL–TC ap-
peared comparable to those in the LDL–apo B-100, indicating
Table I. Plasma Apo E Levels
Tg n Zn Total apoE Mouse apoE Rat apoE
mg/dl
2/2 4 Before 19.763.7 19.763.7 0
After 18.461.8 18.461.8 0
1/2 4 Before 22.862.7 15.560.7 7.262.9
After 26.561.2‡i 16.661.4§ 9.962.5i
1/1 4 Before 27.463.5* 17.161.9 10.362.0
After 26.262.3‡ 13.661.1‡i 12.763.2
ETg2/2:LDLRKO (2/2), ETg1/2:LDLRKO (1/2), and ETg1/1:LDL-
RKO mice (1/1) were maintained on a normal chow diet. Blood was
collected before and after treatment with zinc for 2 wk. Plasma apo E
levels were determined by immunoblot analyses as described in Meth-
ods. The values are expressed as means6SD. *P , 0.05 versus before of
2/2; ‡P , 0.001 versus after of 2/2; §P , 0.01 versus after of 1/2 and
2/2; iP , 0.05 after versus before.
Table II. Plasma Lipid Levels
Tg n Zn TC Non–HDL-C HDL-C TG
m/f mg/dl
2/2 15 Before 260668.6 137652.6 121628.1 127655.5
(8/7) After 240660.8* 122644.1 117628.3 104639.0
1/2 29 Before 254654.9 132638.1 122628.6 124636.0
(12/17) After 203650.0§ 105632.5§ 108627.9‡ 128640.2
1/1 16 Before 251646.5 128633.8 122634.7 133642.8
(7/9) After 189631.2§i 87617.4§i 101631.1 132643.8
ETg2/2:LDLRKO (2/2), ETg1/2:LDLRKO (1/2), and ETg1/1:LDL-
RKO mice (1/1) were maintained on a normal chow diet. Blood was
collected before and after treatment with zinc for 2 wk. Plasma TC and
TG levels were determined. HPLC analyses were performed for each
sample. Non–HDL-cholesterol (non–HDL-C) and HDL-C were calcu-
lated from the TC levels and the HPLC profiles. The values are ex-
pressed as means6SD. *P , 0.05, ‡P , 0.01, §P , 0.0001 after versus
before. iP , 0.01 versus after of 2/2.
Figure 2. HPLC profiles of plasma lipoproteins from mice maintained on a normal chow. Plasma was obtained from five male ETg2/2:LDLRKO 
(A, 2/2), ETg1/2:LDLRKO (B, 1/2), and ETg1/1:LDLRKO mice (C, 1/1) maintained on a normal chow and water supplemented with zinc. 
Pooled plasma from each group was subjected to HPLC lipoprotein analysis, and cholesterol contents in effluents were monitored.
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that the overexpression of rat apo E reduced the particle num-
ber of the apo B-100–containing lipoproteins primarily in the
LDL fraction.
SDS/PAGE of apolipoproteins shows that apo B-100, a
predominant apo B species, in the LDL fraction was reduced
in the ETg1/2:LDLRKO and ETg1/1:LDLRKO mice, com-
pared to the ETg2/2:LDLRKO mice (Fig. 3). VLDL and IDL
contained less apo B-100 than LDL, and there was no signifi-
cant difference in its contents between the three types of mice.
Consistent with the immunoblot results (Fig. 1), the ETg1/2:
LDLRKO and ETg1/1:LDLRKO mice contained more apo E
than the ETg2/2:LDLRKO mice, especially in the VLDL frac-
tion. No significant difference was observed in the composition
of the other apolipoproteins such as apo A-I and apo B-48 be-
tween the three types of mice.
Lipoprotein kinetics studies. To clarify how the overex-
pression of rat apo E reduced plasma cholesterol levels even in
the absence of the LDLR, lipoprotein kinetics studies were
performed (Fig. 4). When injected into wild-type mice with the
functional LDLR, 125I-labeled E1VLDL was cleared faster
than 125I-labeled E2VLDL; their t1/2 were z 15 and 25 min, re-
spectively (Fig. 4 A). The mean FCR of 125I-labeled E1VLDL
were 1.6 times larger than that of 125I-labeled E2VLDL (2.17
versus 1.33 pools/h; P , 0.05).
Next, 125I-labeled E1VLDL or 125I-labeled E2VLDL were
injected into the ETg1/1:LDLRKO or ETg2/2:LDLRKO
mice, respectively (Fig. 4 B). Within the initial 3 h, no significant
difference in plasma clearance of the autologous lipoproteins
was observed; t1/2 5 90 min. After 6 h, however, 125I-labeled
E1VLDL cleared faster than 125I-labeled E2VLDL. Overall,
the mean FCR of 125I-labeled E1VLDL was 1.45 times larger
than that of 125I-labeled E2VLDL (0.33 versus 0.23 pools/h,
P , 0.05). The mean production rate of apo B was calculated
to be 21.2 and 18.4 nmol/h/g body weight for the ETg2/2:LDL-
RKO and ETg1/1:LDLRKO mice, respectively (P , 0.05).
A similar kinetic study was performed using autologous
LDL. There was no difference in the plasma clearance of LDL
between the ETg2/2:LDLRKO and ETg1/1:LDLRKO mice
up to 24 h (data not shown).
A vitamin A fat tolerance test did not reveal any difference
in the plasma excursion of retinyl ester between the three
Table III. Cholesterol, Apo B-100, and Apo B-48 Composition 
in the Plasma Lipoproteins
Tg VLDL IDL LDL HDL
mg/dl
Cholesterol 2/2 26 20 115 75
1/2 35 12 86 82
1/1 25 11 70 80
Apo B-100/Apo B-48 2/2 0.8/1.0 0.2/0.5 89.5/7.0 N.D.
1/2 0.8/1.2 0.2/0.7 69.2/5.3 N.D.
1/1 1.3/1.4 0.3/0.7 50.6/3.8 N.D.
ETg2/2:LDLRKO (2/2), ETg1/2:LDLRKO (1/2), and ETg1/1:LDL-
RKO mice (1/1) were maintained on a normal chow diet. Blood was
collected after treatment with zinc for 2 wk. VLDL, IDL, LDL, and
HDL were isolated by sequential ultracentrifugation and cholesterol
contents were determined enzymatically. Isopropanol precipitation
method was used to determine the total apo B concentrations. Lipopro-
teins were subjected to SDS-PAGE, stained with Coomassie brilliant
blue, and scanned by a densitometer. The concentrations of apo B-100
and apo B-48 were calculated from the values for total apo B and rela-
tive ratio between apo B-100 and apo B-48. N.D. 5 not determined.
Figure 3. Apolipoprotein com-
position of lipoproteins
in ETg2/2:LDLRKO (2/2),
ETg1/2:LDLRKO (1/2), and 
ETg1/1:LDLRKO mice (1/1) 
maintained on a normal chow 
and water supplemented with 
zinc. Pooled plasma isolated 
from 10 mice with indicated ge-
notypes was subjected to se-
quential ultracentrifugation to 
isolate VLDL, IDL, LDL, and 
HDL. Delipidated apoproteins 
equivalent to 20 ml (VLDL and 
IDL) or 10 ml (LDL and HDL) 
of original plasma were sub-
jected to SDS/3–15% PAGE. 
Two separate gels were used; 
one for VLDL, IDL, and HDL, 
and the other for LDL. Protein 
staining with Coomassie brilliant 
blue was performed separately 
for each gel. Therefore, compari-
son of the band intensities be-
tween VLDL, IDL, and HDL 
was valid, but not between these
lipoproteins and LDL. Gels 
were calibrated with Rainbow protein molecular weight markers. The migration positions of apo B-100, apo B-48, apo A-IV, apo E, apo A-I, 
and apo A-II 1 C’s are noted on the right.
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types of mice (Fig. 5 A). The plasma excursion curves for free
retinol were also similar to each other, indicating that no dif-
ference in the absorption of vitamin A existed (Fig. 5 B).
Resistance against diet-induced hypercholesterolemia. The
response of plasma TC and TG levels to the feeding with a
1.25% cholesterol/atherogenic diet was shown in Table IV.
During the feeding, the mice had been maintained on water
supplemented with zinc. The ETg2/2:LDLRKO mice devel-
oped severe hypercholesterolemia with a mean plasma TC
level of 3,116 mg/dl, which is similar to the previously reported
values (16). The ETg1/2:LDLRKO and ETg1/1:LDLRKO
mice exhibited milder hypercholesterolemia compared with
the ETg2/2:LDLRKO mice, indicating that the overexpression
of rat apo E suppressed diet-induced hypercholesterolemia by
23% in the ETg1/2:LDLRKO mice and by 38% in the ETg1/1:
LDLRKO mice, even in the absence of the functional LDLR.
Lipoprotein analyses showed that the TC contents were re-
duced in CM1VLDL and in IDL, but not in LDL (Table V).
Figure 4. Plasma kinetics of 125I-labeled VLDL. VLDL were isolated 
from either ETg2/2:LDLRKO (s) or ETg1/1:LDLRKO mice (d) 
that had been maintained on a normal chow and water supplemented 
with zinc, by ultracentrifugation at a density of 1.006 g/ml, and re-
floated at same density. The same lipoprotein preparations as shown 
in Fig. 1 C were used for radioiodination by iodine monochloride 
method. Specific activities of labeled lipoproteins were 50–200 cpm/
ng protein. 4 mg protein were injected into the jugular vein of three 
mice, together with the autologous fraction (d . 1.063 g/ml) equiva-
lent to the same amount of plasma from which VLDL originated. At 
the indicated times, blood was collected. Apo B–associated radioac-
tivity was determined using the isopropanol precipitation method as 
previously described (9). The value at 1 min after injection was used 
as 100%. The recipients were wild-type mice (A), and autologous 
ETg2/2:LDLRKO and ETg1/1:LDLRKO mice that had been main-
tained on a normal chow and water supplemented with zinc (B).
Figure 5. Vitamin A tolerance test. Aqueous retinyl palmitate (2 mg 
per animal) was administered as a bolus through a gastric cannula to 
the ETg2/2:LDLRKO (s), ETg1/2:LDLRKO (d), and ETg1/1:
LDLRKO mice (n) that had been maintained on a normal chow and 
water supplemented with zinc, after a 4-h fast (n 5 5). Blood was col-
lected at the indicated times. Plasma levels of retinyl palmitate (A) 
and free retinol (B) were determined in the pooled plasma.
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The concentrations of plasma apo B measured by SRID were
as follows: 3,05561,103 mg/dl (n 5 6) in the ETg2/2:LDL-
RKO, 1,50561,093 mg/d (n 5 8) in the ETg1/2:LDLRKO, and
8876715 mg/dl (n 5 11) in the ETg1/1:LDLRKO mice. ETg1/1:
LDLRKO and ETg1/2:LDLRKO mice had significantly lower
plasma apo B levels than ETg2/2:LDLRKO mice (P , 0.05
and , 0.001, respectively).
Suppression of diet-induced atherosclerosis. We compared
the cross-sectional lesion areas in the aortic sinus from the
ETg2/2:LDLRKO and ETg1/1:LDLRKO mice after feeding
with a 1.25% cholesterol/atherogenic diet (Fig. 6). The lesion
areas of the ETg1/1:LDLRKO mice were significantly
smaller than those of the ETg2/2:LDLRKO mice by 45%
(124,603641,464 [n 5 14] versus 68051630525 mm2 [n 5 16],
P , 0.001).
Discussion
The present study has demonstrated that overexpression of
apo E reduces plasma cholesterol levels even in the absence of
the functional LDLR. The cholesterol lowering appears to re-
sult from the reduction of the apo B-100–containing lipopro-
teins in LDL. From the results of the lipoprotein kinetics stud-
ies, we speculate that both the decreased production and the
increased clearance of VLDL, but not the changes in chylomi-
cron metabolism, account for the cholesterol-lowering in the
LDLRKO mice overexpressing rat apo E. Furthermore, the
overexpression of rat apo E suppressed diet-induced hyper-
cholesterolemia as well as atherosclerosis.
We have previously shown that mice overexpressing apo E
have decreased levels of plasma TC and TG, and are resistant
to diet-induced hypercholesterolemia (13, 14). Lipoproteins
kinetics studies showed the increased plasma clearance of lipo-
proteins such as VLDL and LDL. However, it remains un-
known whether the increased clearance of the lipoproteins was
mediated through the LDLR. The present study has clearly
demonstrated that the overexpression of rat apo E has choles-
terol-lowering effects even in the absence of the functional
LDLR, indicating that the non-LDLR pathway is also in-
volved in the cholesterol lowering by the apo E transgene.
Plasma apo B-100 concentrations were reduced in mice
that overexpressed apo E (Fig. 3 and Table III), corroborating
the idea that the reduction of non–HDL-C levels is due to a
decrease in the particle number of apo B–containing lipopro-
teins, but not to a decrease in the cholesterol contents in each
lipoprotein particle. E1VLDL was enriched with rat apo E
compared to E2VLDL (Fig. 1), and cleared faster than
E2VLDL when injected into wild-type mice with the func-
tional LDLR (Fig. 4 A), indicating that E1VLDL has higher
affinity for the LDLR than E2VLDL. When E2VLDL or
E1VLDL were injected back into the LDLRKO mice from
which the respective VLDL were isolated (Fig. 4 B), their
plasma clearance rates were four- and sixfold slower than the
values for the experiments where wild-type mice were used as
recipients. These results indicate that the LDLR has over-
whelming contribution to the clearance of these lipoproteins.
The difference in the plasma clearance between E2VLDL
and E1VLDL was not discernible in the initial 3 h, but
E1VLDL was cleared faster than E2VLDL after 6 h. As a
whole, E1VLDL had higher FCR and lower production rate
Table IV. Effects of Cholesterol Feeding on the Plasma
Lipid Levels
Tg n Zn TC TG
m/f mg/dl
2/2 15 Before 297673 121633
(8/7) After 311661025 101659
1/2 27 Before 284648 111628
(11/16) After 23946893* 73655
1/1 15 Before 294647 131640
(6/9) After 19186632‡ 66640
ETg2/2:LDLRKO (2/2), ETg1/2:LDLRKO (1/2), and ETg1/1:LDL-
RKO mice (1/1) were initially maintained on a normal chow, and then
on a 1.25% cholesterol/atherogenic diet and water supplemented with
zinc for 14 wk. Blood was collected before and after the feeding. Plasma
TC and TG levels were determined enzymatically. HPLC analyses were
performed for each sample. Non–HDL-cholesterol (non–HDL-C) and
HDL-C were calculated from the TC levels and the HPLC profiles. The
values are expressed as means6SD. *P , 0.05, ‡P , 0.01.
Table V. Cholesterol Contents in the Lipoprotein Fraction after 
Cholesterol Feeding
Tg CM/VLDL IDL LDL HDL
mg/dl
2/2 968 1010 336 8
1/2 475 990 362 29
1/1 284 694 331 48
ETg2/2:LDLRKO (2/2), ETg1/2:LDLRKO (1/2), and ETg1/1:LDL-
RKO mice (1/1) were initially maintained on a normal chow, and then
on a 1.25% cholesterol/atherogenic diet and water supplemented with
zinc for 14 wk. Blood was collected after the feeding. VLDL, IDL, LDL,
and HDL were isolated by sequential ultracentrifugation, and their cho-
lesterol contents were determined.
Figure 6. Lipid staining lesion area in the mouse aorta. After feeding 
a 1.25% cholesterol/atherogenic diet and water supplemented with 
zinc for 14 wk, the hearts with aortic roots were taken for the evalua-
tion of fatty streak lesion areas. The mean lesion area per section is 
plotted in each of the ETg2/2:LDLRKO (s) and ETg1/1:LDLRKO 
mice (d). *denotes the difference at P , 0.001.
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than E2VLDL, even when injected into mice lacking the
LDLR.
Apo E secreted from the liver has been thought to be an
important determinant of the clearance of lipoproteins. This
secretion–recapture model was initially proposed to explain
the local autocrine and paracrine-like function of apo E (1, 25),
and was subsequently extended to explain the rapid clearance
of CR (26). In agreement with this model, the enhanced clear-
ance of E1VLDL via the non-LDLR pathway may, at least in
part, reduce the apo B-100 levels in the LDLRKO mice ex-
pressing rat apo E. In addition, VLDL production was reduced
in these animals. We speculate that nascent VLDL acquires
excess apo E in the space of Disse, and then is sequestered
onto the surface of the hepatocytes followed by endocytosis
through a pathway distinct from the LDLR, presumably LRP
or heparan sulfate proteoglycans.
In contrast to our previous report showing that the plasma
TG levels were markedly reduced in mice expressing apo E
(13), the plasma TG levels in the ETg1/2:LDLRKO and ETg1/1:
LDLRKO were similar to those in the ETg2/2:LDLRKO
mice. This discrepancy can be explained by assuming that the
TG-lowering effect of the apo E transgene requires the LDLR,
indicating that the apo E transgene preferentially stimulates
the catabolism of TG-rich lipoproteins through the LDLR-
mediated pathway.
With respect to chylomicron metabolism, the excursion of
the plasma retinyl ester after vitamin A load was delayed nine-
fold in the LDLRKO mice, compared to wild-type mice (13).
These observations are consistent with our previous findings
that the LDLR plays a pivotal role in the metabolism of chylo-
micron (27). In the present study, however, no significant dif-
ference was observed in the plasma excursion of retinyl ester
between the LDLRKO mice with and without the apo E trans-
gene (Fig. 5), which is apparently contradictory to the changes
in the VLDL metabolism. This can be explained by the facts
that apo E is not overproduced in the intestine (13), and that
the intestine lacks such space for enrichment with apo E as the
space of Disse.
Diet-induced hypercholesterolemia was suppressed in the
LDLRKO mice overexpressing rat apo E in both a homozy-
gous or heterozygous state (Table IV). In parallel, diet-induced
fatty streak lesion formation was suppressed in the ETg1/1:
LDLRKO mice (Fig. 6). Because the lesion formation and hy-
percholesterolemia were suppressed to a similar degree, the
cholesterol-lowering effects of the apo E transgene may largely
account for the antiatherogenic effects.
Recently, we and other investigators have reported that the
introduction of genes such as lipoprotein lipase (11), VLDL
receptor (28, 29), APOBEC-1 (30), or cholesterol 7a-hydroxy-
lase (31), which are apparently irrelevant to the LDLR, ame-
liorated hypercholesterolemia in the LDLRKO mice. This
kind of strategy may help avoid potential problems such as au-
toantibody formation against genetically introduced proteins.
Pharmaceutical or genetic manipulation of the hepatic apo E
production should be a promising adjunctive therapy for ho-
mozygous familial hypercholesterolemia.
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